PRKAA1 and acute lymphoblastic leukemia: These experiments demonstrated that there was an additive/synergistic antileukemic effect between the AMPK inhibitor (Compound C) and GANT-61 in all T-ALL cell lines and PDX samples tested (Figure 5A–G and Supplementary Figure S3).